Expanding the Clinical Utility of HER2 as a Multi-Tumor Target, Overcoming Resistance Mechanisms & Optimizing Pharmacology of Next Generation Anti-HER2 Drugs The momentum in anti-HER2 drug development is impossible to ignore: Outcomes for HER2-expressing breast cancer are patients constantly improving; advancements in diagnostics, trial design and
14-16 June 2022